Fluorochrome conjugated anti human eomes mab

Fluorochrome conjugated anti-human mAb specific to HLA-A2, CD3, CD8, CD28, CD38, CD40L, CD69, ICOS, TCRαβ, CCR7, CD45RO, CD80, CD86, ICOS ligand, IFN-γ, CTLA-4, PD-1, PD-L1, PD-L2, T-bet, granzyme B or Akt were purchased from Becton Dickinson (San Diego, CA). Fluorochrome conjugated anti-human Eomes mAb was purchased from eBioscience (San Diego, CA). Recombinant human IL-2, IL-4, IFN-α and TNF-α were purchased from R&D Systems, and human GM-CSF was obtained from Immunex (Seattle, WA). Lenalidomide (Celgene, Summit, NJ) was reconstituted in 1% DMSO and was used at a final concentration of 5 μM to treat either XBP1-CTL or various tumor cell lines.

Fluorochrome conjugated anti-human mAbs specific to CD3, CD4, CD8, CD25, CD28, CD38, CD40L, CCR7, CD45R0, CD69, CD80, CD83, CD86, CD137 (41BB), CD138, FoxP3, HLA-A2, HLA-ABC, HLA-DP/DQ/DR, IFN-γ, IL-2, TNF-α, PD1, PD-L1, 0X40, AKT (pS473), mTOR (pS2448), NF-κB p65 (pS529), Bcl-6, HIF-1 or T-bet were purchased from Becton Dickinson (San Diego, CA). Fluorochrome-conjugated anti-human Eomes mAb was purchased from eBioscience (San Diego, CA). Recombinant human IL-2, IL-4, IFN-α and TNF-α were purchased from R&D Systems, and human GM-CSF was obtained from Immunex (Seattle, WA). ACY241 was purchased from AdooQ Bioscience (Irvine, CA), and reconstituted in 1% DMSO and stored at – 30 °C until needed.